Tag: thrombolytics
US study finds link between social factors and intravenous thrombolysis rate
For ischaemic stroke patients, social factors like education, neighbourhood and employment may be linked to whether they receive treatment with intravenous, clot-busting drugs, according...
Reteplase demonstrates superiority to alteplase in acute ischaemic stroke trial
Reteplase has demonstrated potential as an alternative to alteplase in patients requiring intravenous thrombolysis (IVT) to treat acute ischaemic stroke, as per the findings...
Basking Biosciences closes US$55 million financing to further reversible stroke thrombolytic
Basking Biosciences has announced the close of US$55 million in financing, which will be used to accelerate clinical development of its novel thrombolytic therapy...
Tenecteplase deemed a safe and feasible adjunct to thrombectomy in ALLY...
Intra-arterial tenecteplase has demonstrated potential as a safe and feasible adjunct to mechanical thrombectomy in patients with acute ischaemic stroke caused by a distal...
Mobile stroke units increase odds of averting strokes and achieving complete...
Receiving intravenous tissue plasminogen activator (IV-tPA) in an ambulance-based mobile stroke unit (MSU) increases the likelihood of averting strokes and the odds of a...
Tenecteplase deemed non-inferior to alteplase in suitable ischaemic stroke patients
The ATTEST-2 trial has found that tenecteplase was non-inferior to alteplase, the more established of the two thrombolytic agents, in suitable acute ischaemic stroke...
Chinese TRACE II trial deems tenecteplase non-inferior to alteplase in ischaemic...
New data on intravenous tenecteplase indicate that it can achieve comparable efficacy and safety to alteplase in treating stroke—and, as such, may be used...
ISC 2023 sees presentation of positive data on new stroke drugs...
New data pointing to the possible advantages held by several drug products in treating acute ischaemic stroke were delivered at the recent International Stroke...
NoNO announces first patient dosed with NoNO-42 in Phase 1 study
NoNO Inc has announced the dosing of the first participant in its Phase 1 clinical trial evaluating NoNO-42—a next-generation neuroprotective drug developed in the...
Tenecteplase offers “incredible opportunity” to optimise thrombolytic stroke treatments
Earlier this year, results from the Canadian AcT (Alteplase compared to tenecteplase) randomised controlled trial (RCT) were delivered for the first time at the...
